Introduction
============

With increasing air pollution, the incidence rate of lung cancer has been increasing annually and ranks first among all malignant tumors ([@b1-ol-0-0-6048]). Among lung cancers, non-small cell lung cancer (NSCLC) accounts for 80%, with chemotherapy as the main treatment method ([@b2-ol-0-0-6048]). Early invasion and metastasis of tumors and drug resistance are important factors that influence the effect of treatment, showing only a 15% 5-year survival rate ([@b3-ol-0-0-6048]). A previous study showed that the subpopulation of tumor cells known as 'tumor stem cells' are capable of invasion and have natural drug-resistance or the ability to acquire drug resistance after mutations ([@b4-ol-0-0-6048]). Previous cell and animal models proved that NSCLC tumors can secrete interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which promote proliferation and differentiation of tumor cells. In contrast, there are few studies on the ability of these molecules to regulate invasion and migration ([@b5-ol-0-0-6048]). As an initiating factor of distant metastasis of malignant tumors, the main feature of the epithelial-mesenchymal transition (EMT) is the change of cell phenotype, including the downregulation of epithelial markers such as E-cadherin, loss of cell polarity, upregulation of vimentin and N-cadherin, the acquisition of expression of other mesenchymal markers, and increased migration and mobility, thus promoting the invasion and metastasis of malignant epithelial tumor cells ([@b6-ol-0-0-6048],[@b7-ol-0-0-6048]). NSCLC is mainly derived from the bronchial and alveolar epithelium, therefore it is speculated that EMT plays an important role in the biological behavior of NSCLC. Based on this hypothesis, the present study was designed to analyze the ability of IL-6 and TNF-α to promote EMT and in turn NSCLC, to provide a reference for clinical diagnosis, treatment, and prognosis of patients with NSCLC.

Patients and methods
====================

### Patients

Sixty-five patients who were admitted to the First Affiliated Hospital of Chengdu Medical College for primary diagnosis of NSCLC from January 2014 to January 2016 were consecutively selected and had pathologically-confirmed disease. Patients who underwent surgery or radiotherapy, had history of chemotherapy, or cases with other pulmonary diseases such as chronic obstructive pulmonary disease and phthisis were excluded. Among patients, there were 37 males and 28 females, with average age of 56.7±12.3 years. According to TNM staging, the patients were divided into seven cases of stage I, 18 cases of stage II, 22 cases of stage III, and 18 cases of stage IV. Additionally, 30 healthy subjects were selected as the control group during the same period, including 15 males and 15 females, with average age of 55.8±14.6 years. The study obtained the approval of the Ethics Committee of the First Affiliated Hospital of Chengdu Medical College and written informed consent of the patients or their families was obtained.

### Research methods

Tumor tissue and adjacent tissue (away from the tumor resection margin with negative character, by at least 5 cm) specimens were obtained from patients with NSCLC, which were used for preparing paraffin sections. In addition, 5 ml peripheral venous blood from patients with NSCLC and the control group were collected, and the supernatant was harvested after centrifugation at 2,000 × g for 20 min, and stored at −20°C. The levels of IL-6, TNF-α, vimentin, E-cadherin, and N-cadherin in tissue samples were measured by RT-PCR and western blot analysis, while the levels of serum IL-6 and TNF-α were measured by enzyme-linked immunosorbent assay (ELISA).

### RT-PCR

Total RNA was extracted with the Qiagen RNeasy mini kit (Qiagen, Berlin, Germany), and the concentration and purity were determined by spectrophotometry. A total of 4,000 ng RNA was used for reverse transcription. The reaction system included 5 µl AMV reverse transcriptase 5X reaction buffer + 2.5 µl dNTPs (10 mmol/l) + 40 U ribonuclease inhibitor + 150 ng of each Oligo d(T)15 Primer and random primers + 30 U AMV reverse transcriptase + RNase-free water for a total volume of 25 µl. The reaction was allowed to proceed for 60 min in a 42°C water bath. The IL-6, TNF-α, vimentin, E-cadherin, N-cadherin, and β-actin gene sequences were retrieved from NCBI ([Table I](#tI-ol-0-0-6048){ref-type="table"}), primers were designed with Primer Premier 5.0, and synthesized by Bao Biological Engineering Co., Ltd. (Dalian, China). The reaction system included 12.5 µl 2X Master Mix + 1 µl of each primer (upstream and downstream) (10 µmol/l) + 2 µl cDNA + 8.5 µl ddH~2~O. The thermal profile was 95°C for 30 sec, 95°C for 5 sec, and 63°C for 30 sec, for a total of 40 cycles. Gene expression was calculated according to the 2^−ΔΔCq^ method.

### Western blot analysis

Total protein from whole tissue samples were extracted according to the instructions of the protein-isolation kit (KangChen Bio-tech, Inc., Shanghai, China). A BCA protein concentration kit (Beijing Biyuntian Technology Co., Ltd., Beijing, China; microplate reader EXL 800 UV was purchased from BioTek Instruments, Inc., Winooski, VT, USA) was used to measure protein concentration. Samples were loaded on gels and separated by SDS-PAGE (separation gel voltage was 120 V) for 2 h (electrophoresis instrument was from Bio-Rad Laboratories, Inc., Hercules, CA, USA). A semi-dry transmembrane instrument (Bio-Rad Laboratories, Inc.) was used for transferring samples to PVDF membranes. PVDF membranes were placed in blocking solution (5% dried skimmed milk in TBST) on a rocking platform for 1 h at room temperature. TBST was used to wash membranes three times for 10 min. Membranes were then sealed in valve bags containing mouse monoclonal IL-6 antibody (dilution, 1:200; cat. no. 12153), mouse monoclonal TNF-α antibody (dilution, 1:200; cat. no. 11948), mouse monoclonal vimentin antibody (dilution, 1:500; cat. no. 3390), mouse monoclonal E-cadherin antibody (dilution, 1:500; cat. no. 5296), mouse monoclonal N-cadherin antibody (dilution, 1:500; cat. no. 14215) or mouse monoclonal β-actin antibody (dilution, 1:50; cat. no. 12262) monoclonal primary antibodies (Cell Signaling Technology, Inc., Danvers, MA, USA), and allowed to incubate with shaking for 2 h at 4°C. Membranes were then washed three times for 10 min with TBST. Next, membranes were incubated with goat anti-mouse secondary antibody (dilution, 1:10,000; cat. no. 926-65010) solution (LI-COR Biosciences, Lincoln, NE, USA) for 30 min at room temperature. PVDF membranes were then placed in TBST buffer while shielded from light. A computer imaging system (Odyssey Imager; LI-COR Biosciences GmbH) was used to analyze protein expression.

### ELISA

IL-6 and TNF-α ELISA kits were from Sigma-Aldrich (St. Louis, MO, USA), and experiments were performed according to the manufacturer\'s instructions. Values were averaged after repeating the experiments twice.

### Statistical analysis

SPSS 20.0 software (IBM, Armonk, NY, USA) was used for statistical analysis. Measurement data are presented as mean ± standard deviation, independent sample t-test was used for inter-group comparisons, and paired t-test was used for comparisons within groups. A Pearson\'s test was used for correlation analyses after normality tests. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Comparison of IL-6, TNF-α, vimentin, E-cadherin, and N-cadherin mRNA expression in tissue samples

IL-6, TNF-α, vimentin, and N-cadherin mRNA expression levels in tumor tissues were significantly higher compared with adjacent tissues, and E-cadherin mRNA expression level was significantly decreased (P\<0.05) ([Table II](#tII-ol-0-0-6048){ref-type="table"}).

### Comparison of IL-6, TNF-α, vimentin, E-cadherin and N-cadherin protein expression in tissue samples

IL-6, TNF-α, vimentin, and N-cadherin protein expression levels in tumor tissues were significantly higher than in adjacent tissues, and E-cadherin protein expression level decreased significantly (P\<0.05) ([Table III](#tIII-ol-0-0-6048){ref-type="table"}).

### Comparison of serum IL-6 and TNF-α levels

The levels of serum IL-6 and TNF-α in patients with NSCLC were significantly higher than those of the control group, and the differences were statistically significant (P\<0.05). Among patients with NSCLC, there were 24 cases with lymph node or distant metastasis (36.9%), and the levels of serum IL-6 and TNF-α were significantly higher than in patients without metastasis (P\<0.05) ([Table IV](#tIV-ol-0-0-6048){ref-type="table"}).

### Correlation analysis

The levels of serum IL-6 and TNF-α level were correlated with the levels of IL-6, TNF-α, vimentin, E-cadherin, and N-cadherin mRNA and protein in tumor tissue. Serum IL-6 and TNF-α levels were positively correlated with IL-6, TNF-α, vimentin, and N-cadherin mRNA and protein levels, while they were negatively correlated with E-cadherin mRNA and protein levels.

Discussion
==========

EMT is the transition from epithelial cells to mesenchymal cells. It is characterized by decreased expression or loss of epithelial cell markers, such as E-cadherin and keratin, and increased expression of mesenchymal cell markers, such as vimentin and N-cadherin. Changes in cell morphology that decrease adhesiveness caused by rearrangements of the cytoskeletal system of tumor cells allow them to easily break away from primary lesions, thus invading and metastasizing to surrounding tissues ([@b8-ol-0-0-6048]). Therefore, EMT is an important mechanism involved in tumor metastasis. This study showed that the levels of vimentin and N-cadherin mRNA and protein in tumor tissues of patients with NSCLC were significantly higher than those of adjacent tissues, while E-cadherin expression level decreased significantly. These observations were consistent with a previous study ([@b9-ol-0-0-6048]). Furthermore, it was previously shown that EMT is related to the invasion and metastasis ability of tumors in liver, breast, prostate and colorectal cancer ([@b10-ol-0-0-6048]). Tumor stem cells can manifest the characteristics of extremely active EMT ([@b11-ol-0-0-6048]). Moreover, p38, AKT/β-catenin, and Wnt5a signaling pathways participate in the occurrence of EMT in tumor stem cells. Inhibiting key signaling molecules in these pathways can significantly inhibit EMT activity and increase the apoptosis or necrosis of tumor cells ([@b12-ol-0-0-6048],[@b13-ol-0-0-6048]).

The occurrence of EMT is closely associated with the tumor microenvironment and inflammation ([@b14-ol-0-0-6048]). Mesenchymal stem cells (MSCs), which have multiple differentiation potential and specific chemotaxis toward tumor tissue, can be used as carriers for targeted delivery of suicide genes, growth factor inhibitors, and oncolytic viruses to tumor tissues ([@b15-ol-0-0-6048]). However, MSCs can also promote tumor growth by immune inhibition, promoting angiogenesis, and by other mechanisms ([@b16-ol-0-0-6048]). When stimulated by the tumor microenvironment or inflammatory mechanisms, MSCs can secrete IL-6 and TNF-α, which promote the occurrence of EMT of tumor cells ([@b17-ol-0-0-6048]). The levels of expression of IL-6 and TNF-α in the tumor tissues and sera from patients with NSCLC increased significantly with the clinical stage of the tumor; vimentin and N-cadherin mRNA and protein levels in tumor tissues increased significantly, while E-cadherin mRNA and protein levels decreased significantly; IL-6 and TNF-α levels were positively correlated with vimentin and N-cadherin mRNA and protein levels in tumor tissues, while they were negatively correlated with E-cadherin mRNA and protein levels. These results indicated that IL-6 and TNF-α played important roles in the occurrence of EMT of tumors ([@b18-ol-0-0-6048]). Our results further demonstrated that serum levels of IL-6 and TNF-α of patients with NSCLC with lymph node or distant metastasis were significantly higher than in patients without metastasis. A previous study showed that IL-6 and TNF-α can promote the proliferation and differentiation of NSCLC and participate in invasion and metastasis, the intervention of which may represent a new method for the treatment of tumors ([@b19-ol-0-0-6048]). Treating A549 lung cancer cells with IL-6 and TNF-α antagonists can distinctly decrease vimentin and N-cadherin expression and increase E-cadherin expression, which indicated that IL-6 and TNF-α have the potential to interfere with the biological characteristics of tumors ([@b20-ol-0-0-6048]).

In conclusion, IL-6 and TNF-α can promote EMT of lung cancer cells, and promote invasion and metastasis, which are associated with tumor recurrence and drug resistance. Inhibiting the expression of IL-6 and TNF-α may represent a new method for the treatment of tumors.

###### 

Gene primer sequences.

  Gene         Sequences                          bp
  ------------ ---------------------------------- -----
  IL-6         F: 5′-GAAAACACCAGGGTCAGCAT-3′      
               R: 5′-CAGCCACTGGTTTTTCTGCT-3′      153
  TNF-α        F: 5′-CTCCTACCCGAACAAGGTCA-3′      
               R: 5′-CGGTCACCCTTCTCCAACT-3′       138
  Vimentin     F: 5′-TGGCCGACGCCATCAACACC-3′      
               R: 5′-CACCTCGACGCGGGCTTTGT-3′      145
  E-cadherin   F: 5′-TGAAGGTGACAGAGCCTCTGGA-3′    
               R: 5′-TGGGTGAATTCGGGCTTGTT-3′      152
  N-cadherin   F: 5′-GCGCGTGAAGGTTTGCCAGTG-3′     
               R: 5′-CCGGCGTTTCATCCATACCACAA-3′   156
  β-actin      F: 5′-GAATCCACTGGCGTCTTCAC-3′      
               R: 5′-CGTTGCTGACAATCTTGAGAGA-3′    160

IL-6, interleukin-6; TNF-α, tumor necrosis-α.

###### 

Comparison of IL-6, TNF-α, vimentin, E-cadherin, and N-cadherin mRNA expression in tissue samples.

  Groups             IL-6            TNF-α           Vimentin        E-cadherin      N-cadherin
  ------------------ --------------- --------------- --------------- --------------- ---------------
  Tumor tissues      0.5264±0.1259   0.4284±0.1321   0.5321±0.1524   0.1252±0.0326   0.4629±0.1022
  Adjacent tissues   0.1203±0.0527   0.1523±0.0326   0.2262±0.0527   0.3529±0.1215   0.1152±0.0629
  t-test             4.623           4.235           4.827           3.629           3.957
  P-value            0.024           0.028           0.022           0.035           0.031

IL-6, interleukin-6; TNF-α, tumor necrosis-α.

###### 

Comparison of IL-6, TNF-α, vimentin, E-cadherin, and N-cadherin protein expression in tissue samples.

  Groups             IL-6        TNF-α       Vimentin    E-cadherin   N-cadherin
  ------------------ ----------- ----------- ----------- ------------ ------------
  Tumor tissues      0.76±0.16   0.62±0.14   0.64±0.13   0.23±0.09    0.66±0.22
  Adjacent tissues   0.24±0.07   0.22±0.08   0.19±0.06   0.75±0.18    0.23±0.10
  t-test             5.123       4.785       4.925       5.234        5.426
  P-value            0.018       0.024       0.020       0.016        0.013

IL-6, interleukin-6; TNF-α, tumor necrosis-α.

###### 

Comparison of serum IL-6 and TNF-α level (ng/l).

  Groups   NSCLC group   Control group   Tumor metastasis in NSCLC group   No metastasis
  -------- ------------- --------------- --------------------------------- ---------------
  IL-6     234.6±43.8    54.7±12.5       336.2±52.6                        152.8±25.9
  TNF-α    86.4±12.3     12.6±5.6        126.4±16.7                        35.2±8.2

IL-6, interleukin-6; TNF-α, tumor necrosis-α. NSCLC, non-small cell lung cancer.
